Medtronic will invest $90M in Anteris Technologies for DurAVR TAVR device development, contingent on a $200M IPO.

Researchers have created a new noninvasive technique for performing a type of artery bypass that may change the future of some coronary surgeries.

The global structural heart devices market is experiencing robust growth, driven by increasing incidences of structural heart diseases, expanded indications for transcatheter products, and a growing ...

Heineken, Chubb, and India stocks are in our panelists’ sights this year. How to assemble your own sports portfolio.

Edwards pushes CMS to expand Medicare TAVR coverage to asymptomatic patients, sparking controversy among physicians over ...

Boston Scientific has told customers to stop using certain stents linked to three deaths, the Food and Drug Administration ...

Boston Scientific has enjoyed success in the cardiac device space, but it continues to look to gain market share elsewhere, ...

MARLBOROUGH, Mass., Jan. 12, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has entered into a definitive agreement to acquire Valencia Technologies Corporation, a ...

Researchers at the NIH and Emory School of Medicine have completed the first minimally invasive coronary artery bypass of the ...

Boston Scientific (BSX) closed the most recent trading day at $97.79, moving +2.42% from the previous trading session. This change outpaced the S&P 500's 0.62% gain on the day. On the other hand, the ...